The current management strategies for community-acquired urinary tract infection.
about
Susceptibility to antibiotics in urinary tract infections in a secondary care setting from 2005-2006 and 2010-2011, in São Paulo, Brazil: data from 11,943 urine culturesExploratory analysis of urinary tract infection using a GC-APCI-MS platform.Treatment duration of febrile urinary tract infection (FUTIRST trial): a randomized placebo-controlled multicenter trial comparing short (7 days) antibiotic treatment with conventional treatment (14 days)Isolation Rate and Clinical Significance of Uropathogens in Positive Urine Cultures of Hemodialysis PatientsBiological cost of single and multiple norfloxacin resistance mutations in Escherichia coli implicated in urinary tract infections.Crystal structures of Klebsiella pneumoniae dihydrofolate reductase bound to propargyl-linked antifolates reveal features for potency and selectivity.Clinical and epidemiological features and prognosis of complicated pyelonephritis: a prospective observational single hospital-based study.Clonal composition of Escherichia coli causing community-acquired urinary tract infections in the State of Rio de Janeiro, Brazil.In vitro antimicrobial resistance of urinary Escherichia coli isolates among U.S. outpatients from 2000 to 2010Antibiotic treatment for urinary tract infections: pharmacokinetic/pharmacodynamic principles.Emerging drugs for bacterial urinary tract infections.Treatment outcomes of oral sitafloxacin in acute complicated urinary tract infection and pyelonephritis.Sticky fibers and uropathogenesis: bacterial adhesins in the urinary tract.Risk factors for infection and colonization with community-associated methicillin-resistant Staphylococcus aureus in the Los Angeles County jail: a case-control studyShort- and long-term cure rates of short-duration trimethoprim-sulfamethoxazole treatment in female dogs with uncomplicated bacterial cystitisEconomic burden of uncomplicated urinary tract infections: direct, indirect and intangible costs.Is 5 days of oral fluoroquinolone enough for acute uncomplicated pyelonephritis? The DTP randomized trial.Efficacy and safety of 3 day versus 7 day cefditoren pivoxil regimens for acute uncomplicated cystitis: multicentre, randomized, open-label trial.Ciprofloxacin for the management of urinary tract infection.The potential impact of biomarker-guided triage decisions for patients with urinary tract infections.Relationship between urinary tract infection categorization and pathogens' antimicrobial susceptibilities.Comparison of the minimum inhibitory, mutant prevention and minimum bactericidal concentrations of ciprofloxacin, levofloxacin and garenoxacin against enteric Gram-negative urinary tract infection pathogens.Treatment of acute uncomplicated cystitis with faropenem for 3 days versus 7 days: multicentre, randomized, open-label, controlled trial.Acute Uncomplicated Cystitis in an Era of Increasing Antibiotic Resistance: A Proposed Approach to Empirical Therapy
P2860
Q30839593-35B399CD-8D1F-49D1-951E-CD2C3111F7AAQ33464305-2F9CEDA0-BFC4-4817-A6C9-B60AA10AA6B1Q33494958-18677A62-AE2E-4AFF-B369-3386422B2B89Q33750410-932BD70F-FBA2-44A3-931E-579F9B1E0E2EQ33836664-574D59A9-3CD5-48C1-B1C0-BCA6DC20212AQ34597438-A9E59003-0A0C-4499-B8B7-6DDF012192BEQ34710133-E92E5FE2-1D7A-4D96-A444-C45E0AAAF92CQ35134800-E0EDAF12-47FB-4D22-A062-DA1B0BC7407FQ35867468-C7F5332D-214D-4F22-927E-C8FA83A34060Q35964763-38283890-014D-4DD3-838A-EC06AE1A11DAQ36150606-5197A29E-69D0-453B-A409-8284DFE8CA9DQ36768202-99A5F8C3-0AA6-4D43-9F20-36DBAABD511CQ36895740-53A79C84-DDB3-40BF-AAD4-A9C8B3DBA0B1Q36970168-E6972F57-CA12-4778-8489-1824C0A67C6DQ36975045-40DFDBA3-0969-4595-BBC6-8D6F7D856374Q37609158-DBEA0721-EF6D-4213-8130-967BBB1F2645Q40065737-AB00471B-0905-48B6-A0BD-A9F5BE1DA520Q40509034-165DB7B6-623D-483D-BB19-22398E3A05E3Q43267045-55B493A0-2AEA-48FF-B4D6-E72B8A552272Q44216994-6D0D19D5-6DE3-4BD0-A2F4-EBF4FDBFE97BQ44999503-52580D7C-FF93-4775-91DF-5022A0B1B471Q46832047-85A691C8-FCA4-4375-81C4-74823416ACA3Q51162245-12D89251-CE48-4E13-8280-3ED163A9A105Q58484104-C53FDD96-DC82-49B2-A91B-AAE8F192303D
P2860
The current management strategies for community-acquired urinary tract infection.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
The current management strategies for community-acquired urinary tract infection.
@ast
The current management strategies for community-acquired urinary tract infection.
@en
type
label
The current management strategies for community-acquired urinary tract infection.
@ast
The current management strategies for community-acquired urinary tract infection.
@en
prefLabel
The current management strategies for community-acquired urinary tract infection.
@ast
The current management strategies for community-acquired urinary tract infection.
@en
P1476
The current management strategies for community-acquired urinary tract infection.
@en
P2093
Thomas M Hooton
P304
P356
10.1016/S0891-5520(03)00004-7
P577
2003-06-01T00:00:00Z